Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats.
Selective serotonin reuptake inhibitors (SSRIs) acting on the serotonin (5-HT) receptors may affect γ-aminobutyric acid (GABA)-ergic transmission. The role of 5-HT in the epileptic hippocampus remains controversial since 5-HT has both convulsive and anticonvulsive effects. We investigated the effects of fluoxetine, paroxetine and citalopram on the GABAergic transmission in the normal and pilocarpine-induced epileptic rat hippocampus using electroencephalogram (EEG), paired-pulse inhibition (PPI) and vesicular GABA transporter (VGAT) immunoreactivity. EEG showed spontaneous spike activities in normal rats treated with citalopram, fluoxetine, or paroxetine. PPIs were reduced in normal rats treated with citalopram or fluoxetine, and this reduction was especially prominent in normal rats treated with citalopram. PPIs were markedly reduced in the epileptic rats treated with citalopram, but not in the epileptic rats treated with paroxetine. Normal rats treated with citalopram or paroxetine showed a greater reduction in the relative density of VGAT immunoreactivity in the hippocampus than the normal control rats. Similarly, epileptic rats treated with citalopram or fluoxetine also showed a greater reduction in the relative density of VGAT immunoreactivity in the hippocampus than the epileptic control rats. These findings suggest that SSRI treatment has a slight influence on GABAergic transmission in the hippocampus. SSRI treatment may increase seizure susceptibility in the normal hippocampus and increase the frequency and intensity of seizures in the epileptic hippocampus. However, whether these differential effects result from a direct effect on GABAergic interneurons or via 5-HT subtype receptors remains to be elucidated.
Choi
Hui-Chul
HC
Department of Neurology, College of Medicine, Hallym University, Chunchon 200-702, South Korea. dohchi@hallym.ac.kr
Kim
Yeong-In
YI
Song
Hong-Ki
HK
Kim
Ji-Eun
JE
Kim
Duk-Soo
DS
Kang
Tae-Cheon
TC
D000704:Analysis of Variance; D000818:Animals; D015283:Citalopram / Q000494:pharmacology; D004569:Electroencephalography; D004827:Epilepsy / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D005473:Fluoxetine / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects* / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D017374:Paroxetine / Q000494:pharmacology; D010862:Pilocarpine; D051381:Rats; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D050495:Vesicular Inhibitory Amino Acid Transport Proteins / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D015283:Citalopram; D005473:Fluoxetine; D017374:Paroxetine; D010862:Pilocarpine; D017367:Selective Serotonin Reuptake Inhibitors; D050495:Vesicular Inhibitory Amino Acid Transport Proteins; D005680:gamma-Aminobutyric Acid; C118623:Slc32a1 protein, rat